CVC Capital Partners completed the acquisition of Therakos business of Mallinckrodt for $925m.

CVC Capital Partners, a Luxembourg-based private equity and investment advisory firm, completed the acquisition of Therakos business of Mallinckrodt, a global specialty pharmaceutical company, for $925m. "Today's announcement underscores our commitment to executing on our strategic priorities and creating value for our stakeholders. This transaction provides the Therakos business with an ideal partner to invest in its continued growth, and we look forward to closely working with CVC to transition Therakos for the benefit of patients, healthcare providers, partners and employees. I thank the Therakos team for their ongoing commitment and dedication to improving the lives of patients," Siggi Olafsson, Mallinckrodt President and CEO.